Purpose: To assess the anatomic and functional outcomes in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF therapy in response to intravitreal faricimab.
Design: Retrospective, interventional, consecutive case series.
Subjects: Patients with previously treated nAMD who received ≥ 4 consecutive injections of faricimab were included. The study period was from March through November 2022.
Methods: Clinical and imaging data were extracted from the electronic medical record. Central foveal thickness (CFT), maximum fibrovascular pigment epithelial detachment (fvPED) height, and Snellen visual acuity (VA) were obtained. Generalized estimating equations were used to analyze the change in CFT, maximum fvPED height, and logarithm of the minimum angle of resolution VA.
Main Outcome Measures: Change in CFT, maximum fvPED height, and Snellen VA before faricimab and after ≥ 4 faricimab intravitreal injections.
Results: During the study period, 218 eyes of 191 patients met inclusion criteria. Mean age was 79.9 (range, 70.6-89.2) years. The mean number of intravitreal anti-VEGF injections received before faricimab was 34.2 (range, 6.4-62). The following results were found after ≥ 4 faricimab injections. Mean logarithm of the minimum angle of resolution VA before switching to faricimab was 0.58 (Snellen VA ∼20/76; range, 20/22-20/264) and was 0.55 (Snellen VA ∼20/71; range, 20/21-20/235; P = 0.20) after switching. Mean maximum fvPED height was 195.0 (range, 50.2-339.8) μm before switching to faricimab and improved to 165.0 (range, 33.6-296.4; P < 0.001) μm after switching. Mean CFT was 354.8 (range, 184.7-524.9) μm before switching to faricimab and improved to 306.6 (range, 144.4-468.8; P < 0.001) after switching. The proportion of eyes with intraretinal fluid was 36.7% (80/218 eyes) before switching, and decreased to 24.8% (54/218 eyes, P < 0.001) after switching. The proportion of eyes with subretinal fluid was 53.2% (116/218 eyes) before switching and decreased to 26.6% (58/218 eyes, P < 0.001) after switching.
Conclusions: Intravitreal faricimab may improve anatomic outcomes in patients with previously treated nAMD, while maintaining VA in the short-term.
Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2023.10.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of pigment epithelium detachment composition indices between neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Int J Retina Vitreous
February 2024
Department of Ophthalmology, UPMC, Pittsburgh, PA, USA.
Article Synopsis
- This study compared changes in pigment epithelium detachment composition indices (PEDCI-F) in patients with neovascular age-related macular degeneration (n-AMD) and polypoidal choroidal vasculopathy (PCV) over one year.
- The research involved analyzing optical coherence tomography (OCT) images from 74 eyes (36 with n-AMD and 38 with PCV) treated with anti-VEGF agents, focusing on the composition and changes in PED lesions at 3, 6, and 12 months.
- The findings showed a slight increase in PEDCI-F in both conditions, with higher levels linked to improved visual acuity and fewer necessary anti-VEGF injections, suggesting different
Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
Ophthalmol Retina
April 2024
The Retina Service of Wills Eye Hospital, Wills Eye Physicians - Mid Atlantic Retina, Philadelphia, Pennsylvania. Electronic address:
Purpose: To assess the anatomic and functional outcomes in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF therapy in response to intravitreal faricimab.
Design: Retrospective, interventional, consecutive case series.
Subjects: Patients with previously treated nAMD who received ≥ 4 consecutive injections of faricimab were included.
Optical coherence tomographic correlates of angiographic subtypes of occult choroidal neovascularization.
Invest Ophthalmol Vis Sci
December 2013
Doheny Eye Institute, Los Angeles, California.
Purpose: To compare the optical coherence tomographic (OCT) correlates of two previously described angiographic subtypes of occult choroidal neovascularization (CNV).
Methods: We retrospectively analyzed 17 consecutive patients with previously untreated occult CNV who underwent both fluorescein angiography (FA) and volume spectral domain (SD)-OCT imaging on the same visit. Planimetric grading was performed on the FA images by certified reading center graders to precisely outline the boundaries of the fibrovascular pigment epithelial detachment (FVPED) and/or late leakage of undetermined source (LLUS) components of occult CNV for each case.
Background: The aim of this paper is to report the incidence of retinal pigment epithelial (RPE) tears in patients treated with ranibizumab for subfoveal fibrovascular retinal pigment epithelial detachment (FVPED) due to occult age-related macular degeneration (AMD).
Material/methods: Thirty patients were treated according to the following schedule: saturation phase, further treatment was based on activity of the degeneration process. Visual acuity (VA), optical coherence tomography (OCT) and fluorescein angiography (FA) parameters were evaluated and compared.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!